The prevention of CD8+ T cell infiltration may explain the resistance observed in recurrent or metastatic HNSCC treated with PD-1–targeting immune checkpoint inhibitors combined with CT, approved as a first-line therapy. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.